Business News • PR NewsWire • Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives

Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives

Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives

SOUTH SAN FRANCISCO, Calif., Jan. 24 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced final data from a randomized, controlled Phase 2 trial of picoplatin in metastatic colorectal cancer (CRC

View More : http://www.prnewswire.com/news-releases/poniard-pharmaceuticals-announces-phase-2-trial-of-picoplatin-in-metastatic-colo...

Releted News by prnewswire

Blanket America Launches With Celebrity PSA at Sundance 2010

Brite Insurance Announces Home Insurance Comparison Tool

Managedcomms Expands Leased Lines Product Range

SC Johnson's Innovative Spirit Soars with New Building on Company's International Headquarters

Rentrak Announces Box Office Numbers for Weekend of January 22, 2010